These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 22934811)

  • 1. The HIV-1 non-nucleoside reverse transcriptase inhibitors (part V): capravirine and its analogues.
    Li X; Zhan P; De Clercq E; Liu X
    Curr Med Chem; 2012; 19(36):6138-49. PubMed ID: 22934811
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Non-nucleoside reverse transcriptase inhibitors (NNRTIs): past, present, and future.
    De Clercq E
    Chem Biodivers; 2004 Jan; 1(1):44-64. PubMed ID: 17191775
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New non-nucleoside reverse transcriptase inhibitors (NNRTIs) in development for the treatment of HIV infections.
    Pauwels R
    Curr Opin Pharmacol; 2004 Oct; 4(5):437-46. PubMed ID: 15351347
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 2,4,5-Trisubstituted thiazole derivatives as HIV-1 NNRTIs effective on both wild-type and mutant HIV-1 reverse transcriptase: Optimization of the substitution of positions 4 and 5.
    Xu Z; Guo J; Yang Y; Zhang M; Ba M; Li Z; Cao Y; He R; Yu M; Zhou H; Li X; Huang X; Guo Y; Guo C
    Eur J Med Chem; 2016 Nov; 123():309-316. PubMed ID: 27484516
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HIV-reverse transcriptase inhibition: inclusion of ligand-induced fit by cross-docking studies.
    Ragno R; Frasca S; Manetti F; Brizzi A; Massa S
    J Med Chem; 2005 Jan; 48(1):200-12. PubMed ID: 15634014
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel indazole non-nucleoside reverse transcriptase inhibitors using molecular hybridization based on crystallographic overlays.
    Jones LH; Allan G; Barba O; Burt C; Corbau R; Dupont T; Knöchel T; Irving S; Middleton DS; Mowbray CE; Perros M; Ringrose H; Swain NA; Webster R; Westby M; Phillips C
    J Med Chem; 2009 Feb; 52(4):1219-23. PubMed ID: 19175319
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fused heterocycles bearing bridgehead nitrogen as potent HIV-1 NNRTIs. Part 4: design, synthesis and biological evaluation of novel imidazo[1,2-a]pyrazines.
    Huang B; Liang X; Li C; Chen W; Liu T; Li X; Sun Y; Fu L; Liu H; De Clercq E; Pannecouque C; Zhan P; Liu X
    Eur J Med Chem; 2015 Mar; 93():330-7. PubMed ID: 25707013
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recent advances in DAPYs and related analogues as HIV-1 NNRTIs.
    Chen X; Zhan P; Li D; De Clercq E; Liu X
    Curr Med Chem; 2011; 18(3):359-76. PubMed ID: 21143120
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel piperidinylamino-diarylpyrimidine derivatives with dual structural conformations as potent HIV-1 non-nucleoside reverse transcriptase inhibitors.
    Chen X; Liu X; Meng Q; Wang D; Liu H; De Clercq E; Pannecouque C; Balzarini J; Liu X
    Bioorg Med Chem Lett; 2013 Dec; 23(24):6593-7. PubMed ID: 24239481
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors: SAR and Lead Optimization Using CoMFA and CoMSIA Studies (1995-2016).
    Vanangamudi M; Poongavanam V; Namasivayam V
    Curr Med Chem; 2017 Nov; 24(34):3774-3812. PubMed ID: 28685686
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Next-generation HIV-1 non-nucleoside reverse transcriptase inhibitors.
    Boone LR
    Curr Opin Investig Drugs; 2006 Feb; 7(2):128-35. PubMed ID: 16499282
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Conformational landscape of the human immunodeficiency virus type 1 reverse transcriptase non-nucleoside inhibitor binding pocket: lessons for inhibitor design from a cluster analysis of many crystal structures.
    Paris KA; Haq O; Felts AK; Das K; Arnold E; Levy RM
    J Med Chem; 2009 Oct; 52(20):6413-20. PubMed ID: 19827836
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optimization of 5-aryloxyimidazole non-nucleoside reverse transcriptase inhibitors.
    Jones LH; Allan G; Corbau R; Hay D; Middleton DS; Mowbray CE; Newman SD; Perros M; Randall A; Vuong H; Webster R; Westby M; Williams D
    ChemMedChem; 2008 Nov; 3(11):1756-62. PubMed ID: 18855969
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HIV-1 NNRTIs: structural diversity, pharmacophore similarity, and implications for drug design.
    Zhan P; Chen X; Li D; Fang Z; De Clercq E; Liu X
    Med Res Rev; 2013 Jun; 33 Suppl 1():E1-72. PubMed ID: 21523792
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro selection of mutations in human immunodeficiency virus type 1 reverse transcriptase that confer resistance to capravirine, a novel nonnucleoside reverse transcriptase inhibitor.
    Sato A; Hammond J; Alexander TN; Graham JP; Binford S; Sugita K; Sugimoto H; Fujiwara T; Patick AK
    Antiviral Res; 2006 Jun; 70(2):66-74. PubMed ID: 16472877
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of the non-nucleoside reverse transcriptase inhibitor lersivirine with its pyrazole and imidazole isomers.
    Jones LH; Allan G; Corbau R; Middleton DS; Mowbray CE; Newman SD; Phillips C; Webster R; Westby M
    Chem Biol Drug Des; 2011 May; 77(5):393-7. PubMed ID: 21352504
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Susceptibility of feline immunodeficiency virus/human immunodeficiency virus type 1 reverse transcriptase chimeras to non-nucleoside RT inhibitors.
    Auwerx J; Esnouf R; De Clercq E; Balzarini J
    Mol Pharmacol; 2004 Jan; 65(1):244-51. PubMed ID: 14722257
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structure-based bioisosterism design, synthesis and biological evaluation of novel 1,2,4-triazin-6-ylthioacetamides as potent HIV-1 NNRTIs.
    Zhan P; Li X; Li Z; Chen X; Tian Y; Chen W; Liu X; Pannecouque C; De Clercq E
    Bioorg Med Chem Lett; 2012 Dec; 22(23):7155-62. PubMed ID: 23084898
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design and synthesis of N₁-aryl-benzimidazoles 2-substituted as novel HIV-1 non-nucleoside reverse transcriptase inhibitors.
    Monforte AM; Ferro S; De Luca L; Lo Surdo G; Morreale F; Pannecouque C; Balzarini J; Chimirri A
    Bioorg Med Chem; 2014 Feb; 22(4):1459-67. PubMed ID: 24457088
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structural optimization of N
    Monforte AM; De Luca L; Buemi MR; Agharbaoui FE; Pannecouque C; Ferro S
    Bioorg Med Chem; 2018 Feb; 26(3):661-674. PubMed ID: 29291935
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.